Referred to the House Committee on Education and Workforce.
The Safe Step Act would add a new section to ERISA requiring group health plans and issuers offering coverage in connection with such plans to maintain a clear, prompt, and transparent exceptions process for medication step therapy (prior authorization that forces patients to try preferred drugs first).
It specifies criteria under which an exception must be granted (ineffectiveness, contraindication, risk of severe harm or loss of function, stability on a drug, etc.), prescribes timelines for determinations (72 hours standard, 24 hours for expedited requests), and requires approved exceptions to remain in effect for at least one year.
Plans must provide forms and allow electronic and paper submissions, permit prescribers or representatives to request exceptions, and publicly provide process information.
The bill is a targeted, technical reform addressing a specific utilization management practice with clear consumer-protection aims and concrete procedural requirements — characteristics that often facilitate legislative movement. At the same time, it imposes administrative duties on plans and PBMs and could raise program costs, creating a focal point for industry resistance. Its moderate complexity and need for rulemaking leave room for negotiation, amendment, or delay, so while passage is plausible, it is not highly likely without coalition-building or inclusion in a broader legislative vehicle.
Relative to its intended legislative type, this bill is a well-specified substantive policy change that prescribes concrete operational mechanisms for exception processes to medication step therapy, sets timelines and reporting requirements, and delegates regulatory authority to the Secretary of Labor. It integrates into ERISA structure and provides measurable reporting elements.
Access vs. cost: Progressives emphasize improved clinical access and patient protections; conservatives emphasize increased costs and weakened utilization controls.
Access vs. cost: Progressives emphasize improved clinical access and patient protections; conservatives emphasize increased costs and weakened utilization controls.
A mainstream liberal would likely view this bill positively as a patient-rights and access measure that reduces harmful delays from step therapy protocols.
They would note the required clinical grounds for exceptions, the tight timelines (especially expedited 24-hour reviews), the one-year duration for granted exceptions, and the PBM reporting provisions as increases in transparency and accountability.
They may see it as a pragmatic federal floor to protect patients in employer plans who face unsafe or clinically inappropriate step edits.
A moderate would likely regard the bill as a reasonable, targeted reform to reduce harm and administrative confusion from step therapy while balancing plan management tools.
They would appreciate the structured timelines, standard form requirement, and reporting for oversight, but would seek clarity on costs, administrative burden, and how the Secretary’s forthcoming regulations will define ‘strictly necessary’ information.
They would be cautious about imposing overly rigid mandates that increase premiums or employer compliance costs and would want fiscal and operational estimates before full endorsement.
A mainstream conservative would likely be skeptical, seeing this as federal intrusion into employer-sponsored health plan design and an added regulatory burden on businesses and insurers.
They would emphasize concerns that the mandate constrains plan management tools like step therapy that control costs and could raise premiums or administrative expenses.
The prohibition on PBM/TPA contract terms that impede reporting and the broad reporting requirements would be viewed as government micromanagement and potential exposure of proprietary contractual arrangements.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
The bill is a targeted, technical reform addressing a specific utilization management practice with clear consumer-protection aims and concrete procedural requirements — characteristics that often facilitate legislative movement. At the same time, it imposes administrative duties on plans and PBMs and could raise program costs, creating a focal point for industry resistance. Its moderate complexity and need for rulemaking leave room for negotiation, amendment, or delay, so while passage is plausible, it is not highly likely without coalition-building or inclusion in a broader legislative vehicle.
The bill has not accumulated any surfaced votes yet.
Access vs. cost: Progressives emphasize improved clinical access and patient protections; conservatives emphasize increased costs and weake…
The bill is a targeted, technical reform addressing a specific utilization management practice with clear consumer-protection aims and conc…
Relative to its intended legislative type, this bill is a well-specified substantive policy change that prescribes concrete operational mechanisms for exception processes to medication step therapy, sets timelines and r…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.